Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Other hematologic neoplasm 1

Conditions

Myelodysplastic Syndromes 175Leukemia, Myeloid, Acute 157Myeloproliferative Disorders 74Leukemia, Myelogenous, Chronic, BCR-ABL Positive 73Precursor Cell Lymphoblastic Leukemia-Lymphoma 56Primary Myelofibrosis 52Leukemia, Myelomonocytic, Chronic 45Lymphoma, Non-Hodgkin 39Leukemia 28Polycythemia Vera 25Hodgkin Disease 25Thrombocythemia, Essential 22Myelodysplastic-Myeloproliferative Diseases 22Multiple Myeloma 21Leukemia, Lymphocytic, Chronic, B-Cell 20Leukemia, Biphenotypic, Acute 19Hematologic Neoplasms 19Neoplasms 17Anemia, Refractory, with Excess of Blasts 15Leukemia, Myeloid, Chronic-Phase 14Sarcoma 13Histiocytosis, Langerhans-Cell 13Glioma 13Recurrence 12Neuroblastoma 12Hematologic Diseases 12Wilms Tumor 11Rhabdoid Tumor 11Osteosarcoma 11Neuroectodermal Tumors, Primitive, Peripheral 11

Interventions

venetoclax 1ruxolitinib 1pevonedistat 1Imatinib Mesylate 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hypereosinophilic Syndrome × Myeloid × 90 days × Clear all
NCT00044304 2026-03-16

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
70 enrolled
Myeloid

Hypereosinophilic Syndrome

NCT03862157 2026-03-11

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
40 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡